HGWM
JAZZ icon

Harvest Group Wealth Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Harvest Group Wealth Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-4
Closed -$1K – 196
2022
Q3 		$1K Hold
4
– – ﹤0.01% 145
2022
Q2 		$1K Buy
+4
New +$616 ﹤0.01% 157

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Harvest Group Wealth Management's JAZZ Position: Q4 2022 in Review

Harvest Group Wealth Management sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2022, closing a stake of 4 shares — an estimated $1K sold.

Harvest Group Wealth Management first reported a position in JAZZ in Q2 2022 and held it in 2 quarters. The position peaked at $1K in Q3 2022. 485 funds tracked by Wall St. Rank hold JAZZ as of Q4 2022.

  • Harvest Group Wealth Management reported no remaining Jazz Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Harvest Group Wealth Management sold 4 Jazz Pharmaceuticals shares in Q4 2022, an estimated $1K.
  • Harvest Group Wealth Management first reported a position in Jazz Pharmaceuticals in Q2 2022 and held it in 2 quarters.
  • Harvest Group Wealth Management's Jazz Pharmaceuticals position peaked at $1K in Q3 2022.
  • 485 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2022.

Based on Harvest Group Wealth Management's 13F filing for Q4 2022, filed 30 Jan 2023.